A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.

Drugs
Andreas AndersenTina Vilsbøll

Abstract

Oral semaglutide (Rybelsus®) is a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) with 94% homology to human GLP-1. It is the first GLP-1RA developed for oral administration, and it comprises a co-formulation of the peptide semaglutide with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, which overcomes the challenges of peptide absorption in the acidic conditions of the stomach. Oral semaglutide is indicated for use as an add-on combination therapy (with other glucose-lowering agents, including insulin) or as a monotherapy (in patients who are intolerant to metformin) for type 2 diabetes when diet and exercise do not provide adequate glycemic control. In an extensive phase III clinical program including patients from across the disease spectrum, treatment with oral semaglutide resulted in effective glycemic control, reductions in body weight, and decreases in systolic blood pressure when used as monotherapy or in combination with other glucose-lowering therapies. Studies showed that oral semaglutide was well tolerated, with a safety profile consistent with the GLP-1RA drug class. The risk of hypoglycemia was low, and the most common adverse events were gastrointestinal, with nausea and diarr...Continue Reading

References

Jan 28, 2010·Diabetes Care·Mark PeyrotLuther B Travis
Nov 16, 2013·Therapeutic Delivery·Benjamin J BrunoCarol S Lim
Aug 27, 2015·Journal of Medicinal Chemistry·Jesper LauThomas Kruse
Oct 30, 2015·Diabetes, Obesity & Metabolism·Sten Madsbad
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Aug 17, 2016·Patient Preference and Adherence·Katie D StewartHeather L Gelhorn
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Jan 22, 2017·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Ann-Christin JacobsenAlexander H Treusch
Apr 7, 2018·Clinical Pharmacokinetics·Charlotte GranhallThomas W Anderson
Apr 26, 2018·Journal of Clinical Pharmacology·Tine A BaekdalThomas W Anderson
May 12, 2018·International Journal of Environmental Research and Public Health·Yoshifumi Saisho
Jun 14, 2018·Expert Opinion on Drug Metabolism & Toxicology·Tine A BækdalCilie W Hansen
Nov 16, 2018·Science Translational Medicine·Stephen T BuckleyLotte Bjerre Knudsen
Apr 30, 2019·Frontiers in Endocrinology·Lotte Bjerre Knudsen, Jesper Lau
May 23, 2019·Drugs in R&D·Kristina S BoyeLuis-Emilio García-Pérez
Jun 12, 2019·The New England Journal of Medicine·Mansoor HusainUNKNOWN PIONEER 6 Investigators
Jul 19, 2019·Clinical Drug Investigation·Katherine A Lyseng-Williamson
Oct 11, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Solomon NuhohoAbby Paine
Dec 14, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Stephen C BainMatthew Capehorn
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association
Dec 22, 2019·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Software Mentioned

SUSTAIN
PIONEER
Peptide InnOvatioN for PIONEER

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Related Papers

Clinical Diabetes : a Publication of the American Diabetes Association
Sally Hughes, Joshua J Neumiller
Clinical Diabetes : a Publication of the American Diabetes Association
Vinh Bui, Joshua J Neumiller
Frontiers in Endocrinology
Mark M Smits, Daniël H Van Raalte
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Michael P KaneCarolina D Solis-Herrera
© 2021 Meta ULC. All rights reserved